


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition for ~~preventing or~~ treating viral infectious diseases comprising a compound represented by the following general formula (I):



wherein

A represents a phenyl group substituted with -OX, or a 3-indolyl group;

X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group, -N(R⁴)(R⁵), =N-OH, =N-OR⁶ or a halogen atom;

R⁴ and R⁵ may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or R⁴ and R⁵ together represent a 3 to 8 membered ring;

R⁶ represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms);


D represents a hydrogen atom or a hydroxyl group; bond E represents a single bond or double bond; R¹, R² and R³ may be the same or different, and each represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear

or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms ;

~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof.

2. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising the compound of formula (I) according to claim 1 represented by the following general formula (I'), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof:



wherein A, B, D, bond E, R¹, R² and R³ are the same as defined in claim 1.

3. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof wherein A represents a phenyl group substituted with -OX at position 4, X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms, or a linear or branched alkynyl group having 2 to 8 carbon atoms.

4. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof, wherein B represents an oxo group, a hydrogen atom, a hydroxyl group or =N-OR⁶.

5. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable

salt thereof, wherein R^1 , R^2 and R^3 may be the same or different and each represent a hydroxyl group, an amino group, or -OZ (wherein Z represents a linear or branched alkyl group having 1 to 4 carbon atoms).


6. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof, wherein A represents a phenyl group substituted with -OX at position 4, X represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, B represents an oxo group, a hydroxyl group or =N-OR⁶, and R^1 , R^2 and R^3 may be the same or different and each represent a hydroxyl group or -OZ (wherein Z represents a linear or branched alkyl group having 1 to 4 carbon atoms).

7. **(Currently Amended)** The pharmaceutical composition according to claim 6 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof, wherein X represents a linear or branched alkyl group having 1 to 8 carbon atoms, a linear or branched alkenyl group having 2 to 8 carbon atoms or a linear or branched alkynyl group having 2 to 8 carbon atoms, B represents an oxo group or a hydroxyl group, and R^1 , R^2 and R^3 each represent a hydroxyl group.


8. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof, wherein A represents a 3-indolyl group.

9. **(Currently Amended)** The pharmaceutical composition according to claim 8 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof, wherein B represents an oxo group or a hydroxyl group, and R^1 , R^2 and R^3 each represent a hydroxyl group.


10. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), ~~a prodrug thereof~~ ~~or~~ or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds indicated below:




No.1




No.2




No.3




No.4




No.5




No.6




No.7




No.8




No.9




No.10




No.11




No.12




No.13







No.14




No.15




21




or and




11. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds indicated below:







No.2



No.3




No.5




No.6

CC(C)C(O)CCCCCCCCC/C=C/C[C@H](O)C[C@@H](C(=O)O)C(=O)OCC1=CC=C(C=C1)COCC=C(C)CCCCCCCCCCCCCCCCC(=O)C[C@H](O)C[C@@H](C(=O)O)C(=O)N[C@@H](C(=O)O)Cc1ccc(O)cc1CCCCCCCCCCCCCCCC(=O)C(O)(C(=O)O)C(=O)OCC1=CC=C(C=C1)CNC(=O)C(O)C(=O)O


WASH_5905647.2




No.14






No.15




21




22




or and




12. **(Currently Amended)** The pharmaceutical composition according to claim 1 comprising a compound of formula (I), ~~a prodrug thereof~~ or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds indicated below:



No.1




No.6



No.7

or and



No.8

13. **(Previously Presented)** The pharmaceutical composition according to claim 1, wherein the viral infectious disease is HCV infection.

14. **(Original)** The pharmaceutical composition according to claim 13, wherein the HCV infection is hepatitis C.


15. **(Cancelled)**

16. **(Cancelled)**

17. **(Cancelled)**

18. **(Cancelled)**

19. **(Cancelled)**
20. **(Cancelled)**
21. **(Currently Amended)** A pharmaceutical composition comprising a compound of formula (I) according to claim 25 ~~claim 15~~, a ~~prodrug thereof~~ or a pharmaceutically acceptable salt thereof.
22. **(Currently Amended)** ~~A method of treating The pharmaceutical composition according to claim 21 for preventing or treating of viral infectious diseases comprising administering a pharmaceutical composition of claim 21 to a subject in need thereof.~~ A method of treating viral infectious disease according to claim 22, wherein the viral infectious disease is HCV infection.
23. **(Currently Amended)** ~~The pharmaceutical composition~~ A method of treating viral infectious disease according to claim 22, wherein the viral infectious disease is HCV infection.
24. **(Currently Amended)** ~~The pharmaceutical composition~~ A method of treating viral infectious disease according to claim 23, wherein the HCV infection is hepatitis C.
25. **(New)** A compound represented by the following general formula (I):



wherein

A represents a phenyl group substituted with -OX;

X represents a linear or branched alkynyl group having 2 to 8 carbon atoms;

B represents a hydrogen atom, a hydroxyl group, an oxo group, -N(R⁴)(R⁵), =N-OH, =N-OR⁶ or a halogen atom;

R⁴ and R⁵ may be the same or different, and each represent a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkenyl group having 2 to 6 carbon atoms, or a linear or branched alkynyl group having 2 to 6 carbon atoms, or R⁴ and R⁵ together represent a 3 to 8 member ring;

R⁶ represents a linear or branched alkyl group having 1 to 8 carbon atoms (which may be substituted with an amino group which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms);


D represents a hydrogen atom or a hydroxyl group;

bond E represents a single bond or double bond;

R^1 , R^2 and R^3 may be the same or different, and each represent a hydrogen atom, a hydroxyl group, an amino group (which may be mono- or di-substituted with a linear or branched alkyl group having 1 to 4 carbon atoms), -OZ, a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms; and,

Z represents a linear or branched alkyl group having 1 to 4 carbon atoms, a linear or branched alkenyl group having 2 to 4 carbon atoms, or a linear or branched alkynyl group having 2 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof.

26. (New) The compound of formula (I) according to claim 25 represented by the following general formula (I'):



(wherein A, B, D, bond E, R^1 , R^2 and R^3 are the same as described in claim 25),
or a pharmaceutically acceptable salt thereof.


27. (New) The compound of formula (I) according to claim 26 wherein B is an oxo group, or a pharmaceutically acceptable salt thereof.

28. (New) The compound of formula (I) according to claim 27 wherein D is a hydrogen atom, and bond E is a double bond, or a pharmaceutically acceptable salt thereof.

29. (New) The compound of formula (I) according to claim 28 wherein R^1 , R^2 and R^3 are each a hydroxyl group, or a pharmaceutically acceptable salt thereof.

30. (New) The compound of formula (I) according to claim 25 wherein X is a 2-butynyl group, or a pharmaceutically acceptable salt thereof.

31. (New) A compound represented by the formula:



or a pharmaceutically acceptable salt thereof.